載入...

Activity-based protein profiling shows heterogeneous signaling adaptations to BRAF inhibition

Patients with BRAF V600E mutant melanoma are typically treated with targeted BRAF kinase inhibitors, such as vemurafenib and dabrafenib. Although these drugs are initially effective, they are not curative. Most of the focus to date has been upon genetic mechanisms of acquired resistance; therefore,...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Proteome Res
Main Authors: Sharma, Ritin, Fedorenko, Inna, Spence, Paige T., Sondak, Vernon K., Smalley, Keiran S.M., Koomen, John M.
格式: Artigo
語言:Inglês
出版: 2016
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642956/
https://ncbi.nlm.nih.gov/pubmed/27934295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jproteome.6b00613
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!